All In Biotech

Drug Trial Radar · NCT00090753

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

An Open-label, Multi-center Study to Document the Efficacy, Safety, and Tolerability of Long-term Administration of RO0503821 in Patients With Chronic Renal Anemia

Last checked: Nov 19, 2026Latest source record: Feb 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,228

Actual

Start

Oct 2004

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 6, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients with renal anemia. Eligible patients were those who were receiving stable maintenance therapy with methoxy polyethylene glycol-epoetin beta or erythropoiesis stimulating agents (ESAs) in Phase II or III clinical studies. They continued to receive methoxy polyethylene glycol-epoetin beta or comparator ESAs at the same weekly dose and by the same route of administration (sc or iv) as in the qualifying studies.

Conditions

  • Anemia

Interventions

  • Methoxy Polyethylene Glycol-Epoetin BetaDrug

    Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.

  • Epoetin alfaDrug

    Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).

  • Epoetin betaDrug

    Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).

  • Darbepoetin alfaDrug

    Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin Concentration to the Last Month of Study ParticipationTime frame: Baseline to the end of the study (Up to 49 Months)

Locations

249 sites in 27 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Covina, California

  • Site not named

    Encino, California

  • Site not named

    Irvine, California

  • Site not named

    Los Alamitos, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Monterey Park, California

  • Site not named

    Mountain View, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Stanford, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Lakewood, Colorado

  • Site not named

    Stamford, Connecticut

  • Site not named

    Ocala, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Maywood, Illinois

  • Site not named

    South Holland, Illinois

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Brooklyn Center, Minnesota

  • Site not named

    Columbus, Mississippi

  • Site not named

    Tupelo, Mississippi

Showing 40 of 249 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.